Fig. 4: Tumor-homing capability of PANP-RAWs in vitro and in vivo.
From: Nanoparticles carrying paclitaxel and anti-miR-221 for breast cancer therapy triggered by ultrasound
A PANP intake by RAW264.7 cells. DAPI for the cell nucleus, DIO for nanoparticles, and WGA for the cell membrane. B Flow cytometry analysis of DIO fluorescence in RAW264.7 cells after incubation with PANPs for 0, 3, 6, 12, and 24 h. C Quantitative analysis of B. D Ultrasound images of PANPs in RAW264.7 cells before and after sonication with different intensities of 0.8–1.8 W/cm2 for different times from 0 to 60 s. E Quantitative analysis of echo signal intensities in D. All comparisons were vs. 0.8 W/cm2. F Transwell analysis of PANP-RAWs in the upper chamber towards the bottom chamber with or without breast cancer cells MDA-MB-231 or 4T1. G Quantitative analysis of F. H Fluorescence analysis of DIO in frozen tissue sections of the breast tumor, lung, kidney, and liver from the breast tumor-burden mice injected with DIO-NP-RAWs through tail-vein. I H&E analysis of DIO in frozen tissue sections of the breast tumor, lung, kidney, and liver from the breast tumor-burden mice injected with DIO-NP-RAWs through tail-vein. Data are presented as the mean ± SEM (n = 3). **P < 0.01.
